TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04015869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopregnanolone
Description: neurosteroid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo
Study: NCT01852279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI-FES
Description: Brain computer Interface delivered Function Electrical Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive muscle stimulation
Description: Functional Electrical stimulation delivered by therapist
Study: NCT02474537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Single 200 mg dose INC280
Study: NCT03874520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video triage
Description: The operator will offer the parent calling regarding the sick child to assess the child on video, as compared to the current standard; on the telephone.
Study: NCT02181439

Intervention type: DEVICE
Group type: OTHER
Intervention: (LLLT Low Level Laser Therapy) SiroLaser advance
Description: Irradiation scanning distance of the mucosa over an area ranging from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction, and the CEJ to the bottom of the vestibule in the vertical direction.
Study: NCT01273506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) ER 50-mg TRF
Description: 50 mg TRF single oral dose
Study: NCT00642122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 0.5mg once daily
Study: NCT01721421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extended treatment time
Description: patients receive extended dialysis treatment time time of 6 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: extended treatment time
Description: patients receive extended dialysis treatment time time of 6 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment time
Study: NCT00642122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 1mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 1mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 2mg once daily
Study: NCT01721421

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment time
Study: NCT03282188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reolysin
Description: Reolysin® is a proprietary isolate of Reovirus Type 3 Dearing, a non-enveloped human reovirus with a genome that consists of 10 segments of double-stranded RNA. The human reovirus possesses an innate ability to replicate specifically in transformed cells possessing an activated Ras signalling pathway, a situation often found in malignant cells. Reovirus has been shown to reach and target melanoma cancer cells.
Study: NCT00642122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 4.00mcg twice daily
Study: NCT00409149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM Approache

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH approach
Description: standard dietary DASH approach in hypertensive patients
Study: NCT02581852

Intervention type: OTHER
Group type: OTHER
Intervention: Cross sectional assessment
Description: Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
Study: NCT03282188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reolysin
Description: Reolysin® is a proprietary isolate of Reovirus Type 3 Dearing, a non-enveloped human reovirus with a genome that consists of 10 segments of double-stranded RNA. The human reovirus possesses an innate ability to replicate specifically in transformed cells possessing an activated Ras signalling pathway, a situation often found in malignant cells. Reovirus has been shown to reach and target melanoma cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. GM-CSF is a key cytokine in the differentiation of dendritic cells. It has been used as an immune adjuvant in therapeutic vaccines in pre-clinical and clinical studies, administered as cytokine released from gene-transduced tumour or stromal cells or as recombinant protein. At low doses GM-CSF may enhance migration and differentiation of dendritic cells to local antigen presentation, and is a potent adjuvant to generate specific systemic anti-tumour efficacy.
Study: NCT02145728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Functional Therapy
Description: Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Exercise Classes
Description: Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
Study: NCT03043989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 6 infusions of Docetaxel with 18 doses clarithromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: 6 infusions of Cabazitaxel with 18 doses clarithromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 18 doses of clarithromycin with either Docetaxel or Cabazitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 18 doses of clarithromycin with either Docetaxel or Cabazitaxel
Study: NCT04232072

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group ESPB
Description: A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Ibuprofen
Description: A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period. In Group Ibuprofen, patients will be administered ibuprofen 800 mgr IV every 8 hours in the postoperative period.
Study: NCT01826487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered as per the dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the arm.
Study: NCT04566354

Intervention type: OTHER
Group type: OTHER
Intervention: Repeated 30-s sprint exercise
Description: Analyze of Interleukin-6 concentration before and after repeated 30-s sprint exercise
Study: NCT01519960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
Study: NCT01266876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab two SC injections in the abdomen only.
Study: NCT01266876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab two SC injections in the abdomen only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab two SC injections in the abdomen only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo two SC injections in the abdomen only.
Study: NCT00315640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 6 mg/mL
Description: One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Suspension Depot, 30 mg/mL
Description: One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 60 mg/mL
Description: One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye

Intervention type: OTHER
Group type: OTHER
Intervention: Anecortave Acetate Vehicle
Description: One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
Study: NCT01077310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivitrol- Intramuscular naltrexone (depot-formulation)
Description: Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
Study: NCT05107596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 64Cu-DOTA-ECL1i
Description: Inject PET Radioisotope for imaging
Study: NCT00742118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colic biopsies
Description: colic biopsies and analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colic biopsies
Description: colic biopsies and analysis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colic biopsies
Description: colic biopsies and analysis
Study: NCT02011477

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural Glide
Description: This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neural Glide
Description: This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural stretching
Description: In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Neural stretching
Description: In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject
Study: NCT02623985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofia
Description: Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuickVue
Description: Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Throat swab culture
Description: Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
Study: NCT02108912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESTT
Description: ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional outpatient
Description: Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
Study: NCT04274257

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double-Blind Placebo
Description: The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of placebo will be administered. In the active drug period, one additional cycle (rituximab) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-Blind Rituximab
Description: The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of rituximab will be administered. In the active drug period, one additional cycle (rituximab) will be administered.
Study: NCT04290195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept 25 MG/ML [Zaltrap]
Description: Intravitreal injection of 1.25 mg of ziv aflibercept in patients
Study: NCT03633097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and Usual care
Description: patients after surgery receive usual care(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet) as well as acupuncture treatment as an adjunctive therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: patients after surgery receive usual care alone(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet)
Study: NCT01017627

Intervention type: OTHER
Group type: OTHER
Intervention: Early anemia diagnosis and treatment
Description: Patients returning to the unit are immediately assessed and treated for anemia

Intervention type: OTHER
Group type: OTHER
Intervention: No change from normal routine
Description: Normal unit policy for labs and anemia treatment
Study: NCT02473198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block Bupivacaine
Description: The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toradol
Description: The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
Study: NCT01194063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil lipid emulsion
Description: daily intravenous administration of Omegaven fish oil emulsion
Study: NCT02293980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3795
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3795
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3795
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezlutifan
Description: Oral administration
Study: NCT03729726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future Foundation 2.0 PREIS Program
Description: The Future Foundation 2.0 PREIS intervention model uses a placed-based collective impact framework to provide a comprehensive intervention model, including: academic support and college and career readiness services, evidence-based social emotional learning instruction to strengthen protective factors and promote healthy transitions to adulthood, and trauma-informed, medically accurate, and age appropriate sexual health education. Moreover, the 2.0 PREIS program model features a unique student advocacy component designed to ensure that youth and their families receive the wraparound supports necessary for their students to remain on track for school success.
Study: NCT04113785

Intervention type: DEVICE
Intervention: Klassic Knee System
Description: At present, all TKA available for surgeons to use are asymmetric where there is a distinct femoral and tibial component for the left knee and a distinct femoral and tibial component for the right knee. The Klassic knee system is a symmetrical knee implant, where the same femoral and same tibial component can be used for either the right or left knee
Study: NCT03981692

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consecutive dual task
Description: 8 weeks and 2 days per week, one session 45 min. Consecutive dual task creates the idea that it may provide more workable work without creating stress while doing secondary task during dual task.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated dual task
Description: 8 weeks and 2 days per week, one session 45 min. Integrated dual task is a proven mode of work that has positive effects on geriatrics
Study: NCT03161340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Patients will take Rapamycin 2 days before IVF until 15 days after IVF
Study: NCT03735004

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial electrostimulation (TES)
Description: Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC) current, or TES with DC only will be administered through the skin electrodes positioned on the patient's head

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrostimulation (TES)
Description: Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC) current, or TES with DC only will be administered through the skin electrodes positioned on the patient's head
Study: NCT02501564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium Codeine
Description: One tablet twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet twice a day
Study: NCT00837876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg taken by mouth 1 time per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinb
Description: 150 mg taken by mouth 1 time per day.
Study: NCT03675516

Intervention type: OTHER
Intervention: No specific intervention
Description: Usual care

Intervention type: OTHER
Intervention: No specific intervention
Description: Usual care
Study: NCT03412149

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini Gastric Bypass
Description: Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux en Y Gastric Bypass
Description: Standardization of the techniques will be guaranteed:~1. Mini Gastric Bypass Arm~2. Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length.